An interventional study of Percutaneous peripheral nerve stimulation system in Complications; Prosthesis, Nervous System, Peripheral, Pain, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-28.
Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.
Among the 247 studies in Pain with a site in China, this one is the 152nd largest by planned enrollment of the 212 interventional ones that give a count, is one of 17 that started in 2022, is one of 117 with no phase, reaches primary completion later than 3 of the 71 other live ones, and was the 139th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:
Yi Duan · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China
Ages 18+
Yingyong Zhou,MD,PhD · Sites in China
Ages 18+
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Lijiang Lv · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 26 · Phase 4 30
First in 1992; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is close to the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 120 across the 212 interventional studies, 169 across the 34 observational. Of the 122 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 247 have an industry lead sponsor. The 10 most frequent:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine has 5 studies filed under Pain — fewer than ten, so there is no comparison to draw.
30 of the studies in Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872826Phase 3The Third Xiangya Hospital of Central South UniversityA Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China | 2027-06-30 |
| NCT07533786Haisco Pharmaceutical Group Co., Ltd.A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | 2026-11-22 |
| NCT06553495Jie ChenA Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy | 2026-11-30 |
| NCT07947511Dove Medical Press LtdOral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy Volunteers | 2026-12-22 |
| NCT07557823Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTranscutaneous Auricular Vagus Nerve Stimulation Combined With Cervical Epidural Injection for Cervical Radiculopathy | 2026-12-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 247 studies in Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial was conducted in a prospective, multicenter, randomized withdrawal design at a designated clinical trial facility. The total sample size for this trial is expected to be 59-62 patients.
One to two subjects were conducted in each study center as a preliminary test. A total of about 3-6 subjects were selected for the pre-test. The pre-test subjects used the test equipment (on state) and were not randomized.
The study was divided into screening/baseline period, treatment period (including test period, random withdrawal period and observation period) and follow-up period.
All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent Peripheral Nerve Stimulation(PNS) surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
This study's planned enrollment of 62 is close to the median of 66 across 8,512 interventional studies indexed under Pain.
Browse Pain studies →Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.
Compared within Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neurologic Manifestations. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Turn on the machine for continuous nerve stimulation
Device: Percutaneous peripheral nerve stimulation system
Turn off the machine
All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
Difference of the mean VAS scores of the experimental group and the control group during the random withdrawal period
(VASEGbase -- VASEGwd) Average - (VASCGbase -- VASCGwd) Average Explanation: VASEGbase was the mean VAS score of subjects in the experimental group at 4 days before the random withdrawal period. VASEGwd was the maximum VAS score of subjects in the experimental group during the random withdrawal period. VASCGbase was the mean VAS score of subjects in the control group at 4 days before the random withdrawal period. The maximum VAS score of subjects in the VASCGwd control group during the random withdrawal period.
Time frame: 7 days after the wire implantation test period
Started Oct 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 25 months is above that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine →